Live: Arista Networks Is Reporting Q1 Earnings. Can $ANET Continue Its 32% YTD Rally?

Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Apr 7, 2017 at 10:55 AM EDT

Aurinia Pharmaceuticals Jumps on Phase 3 Planned Trial

Shares of Aurinia Pharmaceuticals saw a handy gain on Friday after the company announced plans for the development of a…

Chris Lange | Apr 5, 2017 at 1:50 PM EDT

Neothetics Posts Solid Win on Patent Approval

Neothetics saw its stock hit a multiyear high on Wednesday after the firm announced a critical patent approval.

Chris Lange | Apr 4, 2017 at 10:40 AM EDT

Is This the Turnaround Paratek Has Been Looking For?

Shares of Paratek Pharmaceuticals saw a huge gain early on Tuesday after the company provided a critical update on its…

Trey Thoelcke | Apr 4, 2017 at 7:05 AM EDT

Fresh Off IPO, Therapix Biosciences Already Aiming at Tourette’s Phase 3 Trial

The road to a pivotal Phase 3 trial usually takes years following an IPO, but Therapix Biosciences may reach that…

Jon C. Ogg | Apr 3, 2017 at 1:00 PM EDT

Why One Analyst Sees Almost 40% Upside in Integra LifeSciences

Argus likes Integra’s strong growth prospects and its ability to execute on acquisition and mergers that help move the company's…

Chris Lange | Apr 3, 2017 at 12:40 PM EDT

Tocagen Announces Potential Pricing for IPO

Tocagen expects to price more than 7 million shares in the range of $10 to $12 apiece for an initial…

Chris Lange | Apr 3, 2017 at 9:05 AM EDT

Why NovoCure Shares Are Skyrocketing

NovoCure saw its shares skyrocket early on Monday after the firm provided an update for its late-stage cancer trial.

Chris Lange | Mar 31, 2017 at 11:00 AM EDT

Cara Therapeutics Announces Pricing for Secondary Offering

Cara Therapeutics has priced more than 4 million shares of common stock at $18 per share in a secondary offering…

Chris Lange | Mar 31, 2017 at 10:30 AM EDT

How Akari Therapeutics Is Putting Itself on the Map

Shares of Akari Therapeutics saw a handy gain on Friday after the firm announced that the FDA granted a Fast…

Chris Lange | Mar 29, 2017 at 1:50 PM EDT

Why This Key Analyst Has a Mixed View of Vertex’s Win

Vertex Pharmaceuticals shares were jumping after the firm released results from two Phase 3 studies in the treatment of cystic…

Chris Lange | Mar 29, 2017 at 10:10 AM EDT

Tuesday’s Top Biopharma Movers

A few biopharma stocks made massive runs on Tuesday morning as the result of clinical trial results and earnings. Although…

Chris Lange | Mar 28, 2017 at 12:20 PM EDT

Why Catalyst Bio Nearly Tripled

Catalyst Biosciences saw its shares practically triple in Tuesday’s session after the company announced a critical regulatory approval.

Chris Lange | Mar 27, 2017 at 10:30 AM EDT

Short Interest Pulls Back in Major Biotechs

The health care sector in general has rallied since Trump took over the presidency, but now that his repeal of…

Chris Lange | Mar 27, 2017 at 8:35 AM EDT

Major Pharma Short Sellers Couldn’t Make Up Their Minds Before Failed Trump Health Care Vote

The March 15 short interest data have been compared with the previous figures, and short interest in most of these…

Jon C. Ogg | Mar 25, 2017 at 10:10 AM EDT

Analyst Calls for Exponential Upside for Idera Pharmaceuticals

Idera Pharmaceuticals is focused on cancer and rare diseases, and it could be a what traders refer to as a…

1 … 170 171 172 173 174 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Aurinia Pharmaceuticals Jumps on Phase 3 Planned Trial

Neothetics Posts Solid Win on Patent Approval

Is This the Turnaround Paratek Has Been Looking For?

Fresh Off IPO, Therapix Biosciences Already Aiming at Tourette’s Phase 3 Trial

Why One Analyst Sees Almost 40% Upside in Integra LifeSciences

Tocagen Announces Potential Pricing for IPO

Why NovoCure Shares Are Skyrocketing

Cara Therapeutics Announces Pricing for Secondary Offering

How Akari Therapeutics Is Putting Itself on the Map

Why This Key Analyst Has a Mixed View of Vertex’s Win

Tuesday’s Top Biopharma Movers

Why Catalyst Bio Nearly Tripled

Short Interest Pulls Back in Major Biotechs

Major Pharma Short Sellers Couldn’t Make Up Their Minds Before Failed Trump Health Care Vote

Analyst Calls for Exponential Upside for Idera Pharmaceuticals

Live: Arista Networks Is Reporting Q1 Earnings. Can $ANET Continue Its 32% YTD Rally?

Live: Navitas Semiconductor Q1 Earnings Tonight. Can the 676% Surge Survive the Print?

Live: AMD Reports Q1 Earnings Tonight. Will the Stock Continue Its 255% 1-Year Explosion?

Which Big-Box Store Chain Has Dominated 2026: Walmart, Target, or Costco?

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

Jim Cramer Isn’t a Fan of Microsoft After Rough Quarter. Is He Right to Be Skeptical?

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

27% of Americans Own ETFs but Allocate Just 6%, Here's Why That Costs Them Retirement Income

Live: Navitas Semiconductor Q1 Earnings Tonight. Can the 676% Surge Survive the Print?

Which Big-Box Store Chain Has Dominated 2026: Walmart, Target, or Costco?

Health and Healthcare Articles

All Health and Healthcare Articles

Aurinia Pharmaceuticals Jumps on Phase 3 Planned Trial

Neothetics Posts Solid Win on Patent Approval

Is This the Turnaround Paratek Has Been Looking For?

Fresh Off IPO, Therapix Biosciences Already Aiming at Tourette’s Phase 3 Trial

Why One Analyst Sees Almost 40% Upside in Integra LifeSciences

Tocagen Announces Potential Pricing for IPO

Why NovoCure Shares Are Skyrocketing

Cara Therapeutics Announces Pricing for Secondary Offering

How Akari Therapeutics Is Putting Itself on the Map

Why This Key Analyst Has a Mixed View of Vertex’s Win

Tuesday’s Top Biopharma Movers

Why Catalyst Bio Nearly Tripled

Short Interest Pulls Back in Major Biotechs

Major Pharma Short Sellers Couldn’t Make Up Their Minds Before Failed Trump Health Care Vote

Analyst Calls for Exponential Upside for Idera Pharmaceuticals

Live: Arista Networks Is Reporting Q1 Earnings. Can $ANET Continue Its 32% YTD Rally?

Live: Navitas Semiconductor Q1 Earnings Tonight. Can the 676% Surge Survive the Print?

Live: AMD Reports Q1 Earnings Tonight. Will the Stock Continue Its 255% 1-Year Explosion?

Which Big-Box Store Chain Has Dominated 2026: Walmart, Target, or Costco?

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

Jim Cramer Isn’t a Fan of Microsoft After Rough Quarter. Is He Right to Be Skeptical?

Featured Reads

A $360,000 Portfolio That Quietly Pays You More Than the Average Social Security Check

27% of Americans Own ETFs but Allocate Just 6%, Here's Why That Costs Them Retirement Income